Implementing a PROACTive Care Pathway to Empower and Support Survivors of Breast Cancer.
Journal
JCO oncology practice
ISSN: 2688-1535
Titre abrégé: JCO Oncol Pract
Pays: United States
ID NLM: 101758685
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
medline:
14
6
2023
pubmed:
12
6
2023
entrez:
12
6
2023
Statut:
ppublish
Résumé
Optimal comprehensive survivorship care is insufficiently delivered. To increase patient empowerment and maximize the uptake of multidisciplinary supportive care strategies to serve all survivorship needs, we implemented a proactive survivorship care pathway for patients with early breast cancer at the end of primary treatment phase. Pathway components included (1) a personalized survivorship care plan (SCP), (2) face-to-face survivorship education seminars and personalized consultation for supportive care referrals (Transition Day), (3) a mobile app delivering personalized education and self-management advice, and (4) decision aids for physicians focused on supportive care needs. A mixed-methods process evaluation was performed according to the Reach, Effectiveness, Adoption, Implementation and Maintenance framework including administrative data review, pathway experience survey (patient, physician, and organization), and focus group. The primary objective was patient-perceived satisfaction with the pathway (predefined progression criteria for pathway continuation ≥70%). Over 6 months, 321 patients were eligible for the pathway and received a SCP and 98 (30%) attended the Transition Day. Among 126 patients surveyed, 77 (66.1%) responded. 70.1% received the SCP, 51.9% attended the Transition Day, and 59.7% accessed the mobile app. 96.1% of patients were very or completely satisfied with the overall pathway, whereas perceived usefulness was 64.8% for the SCP, 90% for the Transition Day, and 65.2% for the mobile app. Pathway implementation seemed to be positively experienced by physicians and the organization. Patients were satisfied with a proactive survivorship care pathway, and the majority reported that its components were useful in supporting their needs. This study can inform the implementation of survivorship care pathways in other centers.
Identifiants
pubmed: 37307673
doi: 10.1200/OP.23.00016
pmc: PMC10332840
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
353-361Références
Trials. 2014 Jul 03;15:264
pubmed: 24993581
J Clin Oncol. 2018 Jul 10;36(20):2088-2100
pubmed: 29775389
Lancet Oncol. 2020 Jan;21(1):80-94
pubmed: 31838009
BMC Public Health. 2017 Mar 3;17(1):230
pubmed: 28253883
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
CA Cancer J Clin. 2020 Jan;70(1):31-46
pubmed: 31661164
J Cancer Surviv. 2022 Feb;16(1):13-23
pubmed: 35107791
Lancet. 2022 Apr 16;399(10334):1537-1550
pubmed: 35430021
J Oncol Pract. 2018 Feb;14(2):e122-e129
pubmed: 29272200
J Natl Cancer Inst. 2000 Jul 5;92(13):1054-64
pubmed: 10880548
Support Care Cancer. 2022 Nov;30(11):9587-9596
pubmed: 36136246
J Clin Oncol. 2015 Sep 1;33(25):2763-71
pubmed: 26169621
JAMA Netw Open. 2022 Apr 1;5(4):e225118
pubmed: 35420663
CA Cancer J Clin. 2019 Jan;69(1):35-49
pubmed: 30376182
J Public Health Manag Pract. 2016 Jan-Feb;22 Suppl 1:S33-42
pubmed: 26599027
BMC Cancer. 2015 Apr 28;15:321
pubmed: 25927495
JCO Oncol Pract. 2022 Mar;18(3):e304-e312
pubmed: 34606296
Implement Sci. 2019 Jan 5;14(1):1
pubmed: 30611302
Res Nurs Health. 2008 Apr;31(2):180-91
pubmed: 18183564
J Clin Oncol. 2022 Jul 1;40(19):2163-2171
pubmed: 35588469
Ann Oncol. 2022 Nov;33(11):1119-1133
pubmed: 35963481
J Med Internet Res. 2018 Feb 12;20(2):e36
pubmed: 29434011
JMIR Form Res. 2021 May 10;5(5):e28668
pubmed: 33970120
Lancet. 2022 Apr 16;399(10334):1551-1560
pubmed: 35430022
Nurse Res. 2011;18(2):52-62
pubmed: 21319484
J Clin Oncol. 2020 Oct 10;38(29):3439-3448
pubmed: 32783672
J Cancer Surviv. 2022 Nov 14;:
pubmed: 36374435
Blood Adv. 2023 Apr 25;7(8):1507-1512
pubmed: 36005840
BMC Public Health. 2015 Jul 21;15:678
pubmed: 26194350
J Cancer Surviv. 2023 Jun;17(3):906-915
pubmed: 34970715
Internet Interv. 2021 Jul 15;25:100429
pubmed: 34401388
Cancer. 2017 Oct 1;123(19):3825-3834
pubmed: 28621820
Cancer Causes Control. 2018 Dec;29(12):1277-1285
pubmed: 30506490
N Engl J Med. 2018 Dec 20;379(25):2438-2450
pubmed: 30575480
J Clin Oncol. 2019 Apr 1;37(10):809-822
pubmed: 30763176
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-11
pubmed: 35649204
J Clin Oncol. 2022 Jul 1;40(19):2069-2073
pubmed: 35439031
JCO Oncol Pract. 2020 Oct;16(10):e1249-e1254
pubmed: 32726174
Am J Public Health. 2013 Jun;103(6):e38-46
pubmed: 23597377
J Clin Oncol. 2022 Sep 20;40(27):3190-3204
pubmed: 35446677
BMC Public Health. 2013 Jul 16;13:658
pubmed: 23855504
Support Care Cancer. 2016 Mar;24(3):1043-51
pubmed: 26248651
CA Cancer J Clin. 2016 Jan-Feb;66(1):43-73
pubmed: 26641959
J Natl Cancer Inst. 2018 Aug 1;110(8):880-887
pubmed: 29471478
J Clin Oncol. 2013 Mar 1;31(7):961-5
pubmed: 23129741
J Clin Oncol. 2022 Apr 1;40(10):1111-1123
pubmed: 35061509
JCO Oncol Pract. 2023 Apr;19(4):e618-e629
pubmed: 36626700
Ann Oncol. 2019 Nov 1;30(11):1784-1795
pubmed: 31591636
J Clin Oncol. 2022 Jul 1;40(19):2148-2162
pubmed: 35290073
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
J Natl Cancer Inst. 2019 Nov 1;111(11):1120-1130
pubmed: 31095326
J Natl Cancer Inst. 2020 Dec 14;112(12):1183-1189
pubmed: 32333765
Pilot Feasibility Stud. 2021 Feb 3;7(1):40
pubmed: 33536076
BMC Public Health. 2014 Oct 22;14:1095
pubmed: 25339154
JCO Oncol Pract. 2022 Jul;18(7):e1100-e1113
pubmed: 35290096
J Clin Oncol. 2020 Mar 1;38(7):734-743
pubmed: 31834818
J Clin Oncol. 2020 Aug 20;38(24):2762-2772
pubmed: 32568632
J Natl Cancer Inst. 2019 May 1;111(5):442-448
pubmed: 30726949
J Med Internet Res. 2006 Nov 14;8(4):e27
pubmed: 17213046
J Clin Oncol. 2021 Nov 1;39(31):3473-3484
pubmed: 34406839